


FORM PTO-1449 (Modified)			Attorney Docket No.: 20167-000120US		Application No.: 09/423,100	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicant: Dr. Zhong-Ru Gan			
			Filing Date: October 29, 1999		Group: 1798-1647	
Reference Designation			U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
<u>CD</u> AA	6,001,604	12/14/99	Hartman et al.			
<u>CD</u> AB	4,916,212	04/10/90	Markussen et al.			
<u>CD</u> AC	4,342,832	08/03/82	Goeddel et al.			
<u>CD</u> AD	5,254,463	10/19/93	de Boer et al.			
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
<u>CD</u> AE	WO 96/20724	07/11/96	PCT			
<u>CD</u> AF	WO 97/18233	05/22/97	PCT			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
EXAMINER		<u>g. h. l. o. s.</u>		DATE CONSIDERED		<u>11/10/04</u>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 1 of 4

Complete if Known

Application Number	10/054,873
Filing Date	January 22, 2002
First Named Inventor	Zhong-Ru Gan
Art Unit	1647
Examiner Name	Not yet assigned Nichols
Attorney Docket Number	020167-000130US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CS	1	US-4,342,832		08/03/1982	Goeddel et al.	
	2	US-4,816,212		04/10/1990	Markussen et al.	
	3	US-5,254,463		10/19/1993	de Boer et al.	
	4	US-5,358,857		10/25/1994	Stengelin et al.	
	5	US-5,422,110		06/06/1995	Potter et al.	
	6	US-5,473,049		12/05/1995	Obermeier et al.	
	7	US-5,559,128		09/24/1996	Chakrabarty et al.	
	8	US-5,719,021		02/17/1998	Inouye	
	9	US-6,001,604		12/14/1999	Hartman et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
CS	10	EP	0 055 945	A2	07/14/1982	Genentech, Inc.		<input type="checkbox"/>
	11	EP	0 347 781	B1	02/16/1994	Hoechst Aktiengesellschaft		<input type="checkbox"/>
	12	EP	0 845 454	A2	03/29/1995	Lunin et al.		<input type="checkbox"/>
	13	WO	96/20724	A1	07/11/1996	Bio-Technology General Corp.		<input type="checkbox"/>
	14	WO	96/23888	A1	08/08/1996	G.D. Searle & Co.		<input type="checkbox"/>
	15	WO	97/18233	A1	05/22/1997	Pharmacia & Upjohn AB		<input type="checkbox"/>
	16	WO	02/079251	A2	10/10/2002	Novo Nordisk A/S		<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner
SignatureDate
Considered


11/10/04

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

2

of

4

Complete if Known

Application Number	10/054,873
Filing Date	January 22, 2002
First Named Inventor	Gan, Zhong-Ru
Art Unit	1647
Examiner Name	Not yet assigned <i>Nichols</i>
Attorney Docket Number	020167-000130US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>CSN</i>	17	BIOSIS DATABASE, Accession number 199497237023. Samuelsson <i>et al.</i> , 1994, "Enhanced <i>in vitro</i> refolding of insulin-like growth factor I using a solubilizing fusion partner," <i>Biochemistry</i> 33(14):4207-4211 (abstract)	
	18	BIOSIS DATABASE, Accession number PREV199799785120. Klappa <i>et al.</i> , 1997, "Interactions between protein disulphide isomerase and peptides," <i>European Journal of Biochemistry</i> 248(1):37-42 (abstract)	
	19	Bork and Bairoch, 1998, "Go hunting in sequence databases but watch out for the traps," <i>Trends Genet.</i> 12(10):425-427	
	20	Bork, P., 2000, "Powers and pitfalls in sequence analysis: the 70% hurdle," <i>Genome Res.</i> 10(4):398-400	
	21	Brenner, S.E., 1999, "Errors in genome annotation," <i>Trends Genet.</i> 15(4):132-133	
	22	Burgess, "Protein Purification," in <i>Protein Engineering</i> ; Oxender, D.L., Fox, C.F., Eds.; Alan R. Liss, Inc; NY, (1987), pp. 71-82.	
	23	Bumett, J. P., "Commercial Production of Recombinant DNA-Derived Products," in <i>Experimental Manipulation of Gene Expression</i> , Academic Press, NY, (1983), pp. 259-277.	
	24	Castellanos-Serra <i>et al.</i> , 1996, "Expression and folding of an interleukin-2-proinsulin fusion protein and its conversion into insulin by a single step enzymatic removal of the C-peptide and the N-terminal fused sequence," <i>FEBS Letters</i> , 378:171-176.	
	25	Chance <i>et al.</i> , "Chemical, Physical, and Biological Properties of Recombinant Human Insulin," in J. L. Gueriguan <i>Insulins, Growth Hormone, and Recombinant DNA Technology</i> , Raven Press, NY, (1981), pp. 71-85.	
	26	Chance <i>et al.</i> , "The Production of Human Insulin Using Recombinant DNA Technology and a New Chain Combination Procedure," in <i>Peptides: Synthesis-Structure-Function</i> , Pierce Chem. Co., Rockford, IL, (1981), pp. 721-728.	
	27	Diers <i>et al.</i> , "Yeast Fermentation Processes for Insulin Production," in Y. H. Chiu, <i>Drug Biotechnology Regulations: Scientific Basis and Practices</i> , Marcel Dekker, Inc., NY, (1991), pp. 166-176.	
	28	Doerks <i>et al.</i> , 1998, "Protein annotation: detective work for function prediction," <i>Trends Genet.</i> 14(6):248-250	
<i>✓</i>	29	Etienne-Decent, "Regulation of Protein Synthesis," in <i>Genetic Biochemistry: From Gene to Protein</i> , Ellis Horwood Limited, Chichester, U.K., (1988), pp. 125-127.	
<i>CSN</i>	30	Frank and Chance, "The Preparation and characterization of human insulin of recombinant DNA origin," in <i>Therapeutic Agents Produced by Genetic Engineering "Quo Vadis?" Symposium</i> , (May 29-30, 1985), Sanoff Group, Toulouse-Labège, France, pp. 137-148.	

Examiner
Signature*G. Nichols*Date
Considered

11/10/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

3

of

4

Complete if Known

Application Number

10/054,873

Filing Date

January 22, 2002

First Named Inventor

Gan, Zhong-Ru

Art Unit

1647

Examiner Name

Not yet assigned NICHOLS

Attorney Docket Number

020167-000130US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
gan	31	Frank and Chance, 1983, "Two Routes for Producing Human Insulin Utilizing Recombinant DNA Technology," <i>Munch. Med. Wschr.</i> 125(Suppl. 1):pp. S14-S20.	
	32	Goeddel et al., 1979, "Expression in <i>Escherichia coli</i> of chemically synthesized genes for human Insulin," <i>Proc. Natl. Acad. Sci. USA</i> 76(1): 106-110.	
	33	Ikehara et al., 1984, "Synthesis of a gene for human growth hormone and its expression in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 81:5956-5960.	
	34	Inouye, M., 1991, "Intramolecular Chaperone: The Role of the Pro-Peptide in Protein Folding," <i>Enzyme</i> 45:314-321.	
	35	Johnson, 1983, "Human Insulin from Recombinant DNA Technology," <i>Science</i> 219:632-637.	
	36	Johnson, R. D., 1986, "The Processing of Biomacromolecules: A Challenge for the Eighties," <i>Fluid Phase Equilib.</i> 29:109-123.	
	37	Kroeff et al., 1989, "Production Scale Purification of Biosynthetic Human Insulin by Reversed-Phase High-Performance Liquid Chromatography," <i>Journal of Chromatography</i> 461: 45-61.	
	38	Ladisch and Kohlmann, 1992, "Recombinant Human Insulin," <i>Biotechnol. Prog.</i> 8:469-478.	
	39	Ngo et al., "Computational complexity, protein structure prediction, and the Levinthal Paradox," In: <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz and Le Grand, eds. Birkhauser, Boston, MA, 1994, pp. 433-508.	
	40	Norman and Litwack, "Pancreatic Hormones: Insulin and Glucagon," in <i>Hormones</i> , Academic Press, Inc., NY, (1987), pp 264-317.	
	41	Shinde and Inouye, 1993, "Intramolecular chaperones and protein folding," <i>TIBS</i> 18:442-446.	
	42	Skolnick and Fetrow, 2000, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends Biotechnol.</i> 18(1):34-39	
	43	Smith and Zhang, 1997, "The challenges of genome sequence annotation or 'the devil is in the details,'" <i>Nat. Biotechnol.</i> 15(12):1222-1223	
	44	Thim et al., 1986, "Secretion and processing of insulin precursors in yeast," <i>Proc. Natl. Acad. Sci. USA</i> 83:6766-6770.	

Examiner
SignatureDate
Considered

11/10/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 4 of 4

Compleat if Kn wn

Application Number	10/054,873
Filing Date	January 22, 2002
First Named Inventor	Gan, Zhong-Ru
Art Unit	1647
Examiner Name	Not yet assigned NICHOLS
Attorney Docket Number	020167-000130US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SW	45	Tottrup and Carlsen, 1990, "A Process for the Production of Human Proinsulin in <i>Saccharomyces cerevisiae</i> ," <i>Biotechnol. Bioeng.</i> 35:339-348.	
SW	46	Villa-Komaroff <i>et al.</i> , 1978, "A bacterial clone synthesizing proinsulin," <i>Proc. Natl. Acad. Sci. USA</i> 75(8):3727-3731.	
	47	Watson <i>et al.</i> , <i>Recombinant DNA—A Short Course</i> , Scientific American Books, W.H. Freeman Co., NY, (1983), pp. 231-241.	
	48	Wells, J. A., 1990, "Additivity of mutational effects in proteins," <i>Biochemistry</i> 29(37):8509-8517	
V	49	Wheelwright, <i>Protein Purification: Design and Scale up of Downstream Processing</i> , Oxford University Press; NY, (1991), p.217.	
SW	50	Williams <i>et al.</i> , 1982, "Cytoplasmic Inclusion Bodies in <i>Escherichia coli</i> Producing Biosynthetic Human Insulin Proteins," <i>Science</i> 215:687-689.	

Examiner
SignatureDate
Considered

11/10/04

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/054,873		
		Filing Date	January 22, 2002		
		First Named Inventor	Gan, Zhong-Ru		
		Art Unit	1647		
Sheet	1	of	2	Examiner Name	Christopher J. Nichols
				Attorney Docket Number	020167-000130US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1.	4,665,160 A	05-12-1987	Seeburg	
	2.	2002/0164712 A1	11-07-2002	Gan	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	3.	CA	1,341,211		03-27-2001	Hoechst Aktiengesellschaft		<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	11/10/04
-----------------------	--	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60267747 v1



PTO/SB/08B (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/054,873
		Filing Date	January 22, 2002
		First Named Inventor	Gan, Zhong-Ru
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
Sheet 2	of 2	Attorney Docket Number	020167-000130US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
gan	4.	CATTINI & EBERHARDT, "Regulated expression of chimeric genes containing the 5'-flanking regions of human growth hormone-related genes in transiently transfected rat anterior pituitary tumor cells" Nucleic Acids Research 15(3):1297-1309 (1987).	—
I	5.	GELI et al., "Synthesis and sequence-specific proteolysis of a hybrid protein (colicin A: growth hormone releasing factor) produced in Escherichia coli" Gene 80(1):129-136 (1989).	—
I	6.	HIRT et al., "The human growth hormone gene locus: structure, evolution, and allelic variations" DNA 6(1):59-70 (1987).	—
I	7.	LIEBHABER et al., "Synthesis of growth hormone-prolactin chimeric protein and processing mutants by the exchange and deletion of genomic exons" Journal of Biological Chemistry 261:14301- 14306 (1986).	—
gan	8.	MOORE & KELLY, "Re-routing of a secretory protein by fusion with human growth hormone sequences" Nature 321(6068):443-446 (1986).	—

Examiner Signature		Date Considered	11/10/04
-----------------------	--	--------------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.